Skip to main content
Log in

Surgery, Tamoxifen, Carboplatin, and Radiotherapy in the Treatment of Newly Diagnosed Glioblastoma Patients

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

A historically controlled phase II study was undertaken to investigate the efficacy and toxicity of a postoperative treatment consisting of high-dose continuous tamoxifen, carboplatin and radiotherapy in patients with newly diagnosed glioblastoma. Between 1995 and 1998, 50 patients with newly diagnosed glioblastomas underwent surgery and were subsequently treated with 200 mg day−1 tamoxifen continuously, 3 cycles of carboplatin (300 mg m−2), and radiotherapy. Survival data for a historical control group were calculated from respective prognostic indices and were obtained from studies with comparable patient populations treated with operation and radiotherapy only. In our study, the median time to tumor progression was 30 weeks and the median survival time (MST) 55 weeks (95% confidence interval: 46–63 weeks). The MST of the control group (48 weeks) showed to be within this interval. In addition to already known prognostic factors in malignant gliomas (age, Karnofsky performance score, extent of tumor resection), the gender (females lived longer than males, p = 0.0025) showed to influence survival. Serious side effects (thrombosis, pulmonary embolism) occurred in 6 patients. A high incidence of multifocal tumor recurrences (33%), which might be related to study-treatment, was observed. In conclusion, the combined therapy failed to demonstrate a higher efficacy than standard treatment for glioblastoma patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Legha SS: Tamoxifen in the treatment of breast cancer. Ann Intern Med 109: 219-228, 1988

    Google Scholar 

  2. Pollack IF, Randall MS, Kristofik MP, Kelly RH, Selker RG, Vertosick Jr FT: Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro. Cancer Res 50: 7134-7138, 1990

    Google Scholar 

  3. Stojkovic RR, Jovancevic M, Santel DJ, Grcevic N, Gamulin S: Sex steroid receptors in intracranial tumors. Cancer 65: 1968-1970, 1990

    Google Scholar 

  4. Baltuch GH, Couldwell WT, Villemure JG, Yong VW: Protein kinase C inhibitors suppress cell growth in established and low-passage glioma cell lines. A comparison between staurosporine and tamoxifen. Neurosurgery 33: 495-501, 1993

    Google Scholar 

  5. Puchner MJA, Giese A: Tamoxifen-resistant glioma-cell-subpopulations are characterized by increased migration and proliferation. Int J Cancer 86: 468-473, 2000

    Google Scholar 

  6. Couldwell WT, Antel JP, Yong VW: Protein kinase C activity correlates with the growth rate of malignant gliomas: part II: effects of glioma mitogens and modulators of protein kinase C. Neurosurgery 31: 717-724, 1992

    Google Scholar 

  7. Nishizuka Y: Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258: 607-614, 1992

    Google Scholar 

  8. Couldwell WT, Weiss MH, DeGiorgio CM, Weiner LP, Hinton DR, Ehresmann GR, Conti PS, Apuzzo MLJ: Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 32: 485-490, 1993

    Google Scholar 

  9. Vertosick Jr FT, Selker RG, Pollack IF, Arena V: The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: preliminary results in a series of 'failed' patients. Neurosurgery 30: 897-903, 1992

    Google Scholar 

  10. McClay EF, McClay MET: Tamoxifen: is it useful in the treatment of patients with metastatic melanoma? J Clin Oncol 12: 617-626, 1994

    Google Scholar 

  11. Pass HW, Temeck BK, Kranda K, Steinberg SM, Pass HI: A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction. Ann Surg Oncol 2: 214-220, 1995

    Google Scholar 

  12. Hoff von DD: Whither Carboplatin?-A replacement for or an alternative to Cisplatin? J Clin Oncol 5:169-171, 1987

    Google Scholar 

  13. Cristante L, Siepmann G, Westphal M, Hagel C, Herrmann HD: Superselective intraarterial cisplatin application for recurrent malignant gliomas. Reg Cancer Treat 4: 188-194, 1992

    Google Scholar 

  14. Donsson AM, Weil MD, Foreman NK: Tamoxifen radiosensitization in human glioblastoma cell lines. J Neurosurg 90: 533-536, 1999

    Google Scholar 

  15. EORTC Brain Tumor Group: Cisplatin does not enhance the effect of radiation therapy in malignant gliomas. Eur J Cancer 27: 568-571, 1991

    Google Scholar 

  16. Lunardi P, Farah JO, Mastronardi F, Puzzilli F, Lo Bianco FM: Intravenous administration of high doses of carboplatin in multimodal treatment of high grade gliomas: a phase II study. Acta Neurochir (Wien) 138: 215-220, 1996

    Google Scholar 

  17. Zhang W, Yamada H, Sakai N, Niikawa S, Nozawa Y: Enhancement of radiosensitivity by tamoxifen in C6 glioma cells. Neurosurgery 31: 725-730, 1992

    Google Scholar 

  18. Irish WD, McDonald DR, Cairncross JG: Measuring bias in uncontrolled brain tumor trials-to randomize or not to randomize? Can J Neurol Sci 24: 307-312, 1997

    Google Scholar 

  19. World Health Organization: Handbook for reporting results of cancer treatment. WHO offset publication no.48: Geneva, 1979

  20. Curran Jr WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, Nelson DF: Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. J Natl Cancer Inst 85: 704-710, 1993

    Google Scholar 

  21. Medical Research Council: Prognostic factors for high-grade malignant glioma: development of a prognostic index. A report of the Medical Research Council Brain Tumour Working Party. J Neuro-Oncol 9: 47-55, 1990

    Google Scholar 

  22. Barker II FG, Prados MD, Chang SM, Gutin PH, Lamborn KR, Larson DA, Malec MK, McDermott MW, Sneed PK, Wara WM, Wilson CB: Radiation response and survival time in patients with glioblastoma multiforme. J Neurosurg 84: 442-448, 1996

    Google Scholar 

  23. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958

    Google Scholar 

  24. Cox DR: Regression models and life tables. J R Stat Soc (B) 34: 187-229, 1972

    Google Scholar 

  25. Albert FK, Forsting M, Sartor K, Adams HP, Kunze S: Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 34: 45-61, 1994

    Google Scholar 

  26. Devaux BC, O'FaIIon JR, Kelly PJ: Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 78: 767-775, 1993

    Google Scholar 

  27. Couldwell WT, Hinton DR, Surnock M, DeGiorgio CM, Weiner LP, Apuzzo MLJ, Masri L, Law RE, Weiss MH: Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res 2: 619-622, 1996

    Google Scholar 

  28. Brandes AA, Ermani M, Turazzi S, Scelzi E, Berti F, Amista P, Rotilio A, Licata C, Fiorentino MV: Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study. J Clin Oncol 17: 645-650, 1999

    Google Scholar 

  29. Chamberlain MC, Kormanik PA: Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas. Arch Neurol 56: 703-708, 1999

    Google Scholar 

  30. Chang SM, Barker II FG, Huhn SL, Nicholas MK, Page M, Rabbitt J, Prados MD: High dose oral tamoxifen and subcutaneous interferon alpha-2a for recurrent glioma. J Neuro-Oncol 37 169-176, 1998.

    Google Scholar 

  31. Mastronardi L, Puzzilli F, Couldwell WT, Farah JO, Lunardi P: Tamoxifen and carboplatin combinational treatment of high-grade gliomas. Results of a clinical trial on newly diagnosed patients. J Neuro-Oncol 38: 59-68, 1998

    Google Scholar 

  32. Arita N, Taneda M, Hayakawa T: Leptomeningeal dissemination of malignaht gliomas. Incidence, diagnosis and outcome. Acta Neurochir (Wien) 126: 84-92, 1994.

    Google Scholar 

  33. Barker II FG, Chang SM, Gutin PH, Malec MK, McDermott MW, Prados MD, Wilson CB: Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 42: 709-723, 1998

    Google Scholar 

  34. Hochberg FH, Pruitt A: Assumptions in the radiotherapy of glioblastoma. Neurology 30: 907-911, 1980

    Google Scholar 

  35. Preul MC, Caramanos Z, Villemure JG, Shenouda G, LeBlanc R, Langleben A, Arnold DL: Using proton magnetic resonance spectroscopic imaging to predict in vivo the response to recurrent malignant gliomas of tamoxifen chemotherapy. Neurosurgery 46: 306-318, 2000

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Puchner, M.J., Herrmann, HD., Berger, J. et al. Surgery, Tamoxifen, Carboplatin, and Radiotherapy in the Treatment of Newly Diagnosed Glioblastoma Patients. J Neurooncol 49, 147–155 (2000). https://doi.org/10.1023/A:1026533016912

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1026533016912

Navigation